MELBOURNE, Australia, June 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, attended a keynote address, “Rejuvenation and Health: Science for an Ageing Society,” the title of a new edition of 'Dialogues with Society', an event organized by the Social Council of the University of Granada (UGR), held at the historical Hospital Real, Granada, Spain, first inaugurated in 1526. Dr. Juan Carlos Izpisúa provided the UGR with the keys to science against ageing. Dr. Izpisúa is one of the world's foremost influential scientists in the field of developmental biology and regenerative medicine.
“Propanc’s research into the use of proenzymes to differentiate specific target cells at the core of many age-related diseases is right in the center of this…”The prestigious international researcher Dr. Izpisúa helped to understand the cellular and molecular mechanisms responsible for embryonic development, from the moment of fertilization to the formation of an adult organism composed of millions of cells. These discoveries are having a significant impact on the development of novel treatments for diseases and have contributed to the creation of new frontiers for biomedical science, in fields such as organ and tissue regeneration and the fight against human ageing. The Rector of the UGR, Pedro Mercado, and the President of the Social Council, Teresa Pagés, participated in this meeting. Juan Antonio Marchal Corrales, Professor of Human Anatomy and Embryology at the University of Granada, presented the conference.
“It was an honor to attend the keynote address of Dr. Izpisúa whose scientific interests and vision for the future of humanity are world renowned,” said Mr. Nathanielsz. “Propanc’s research into the use of proenzymes to differentiate specific target cells at the core of many age-related diseases is right in the center of this pioneering field of research. Our collaboration with the Universities of Granada and Jaén will continue to investigate this field of research, specifically cell rejuvenation of tissues relating to diseases such as fibrosis and diabetes, as well as cancer from solid tumors. Given our lead asset, PRP, is on schedule to enter a Phase 1b, First-In-Human study in advanced cancer patients, we are poised to transform this key research into potentially meaningful clinical benefits that could unlock the mystery of many different chronic diseases.”
Dr. Izpisúa belongs to Altos Labs, San Diego Institute of Science (USA), and holds an honorary doctorate from the UGR. The scientist held a meeting prior to the event with the Rector of the University of Granada, Pedro Mercado, in which the vice-rector for the Ceuta and Melilla Campuses, Strategic Planning and Communication, Salvador del Barrio, and the President of the Social Council, Teresa Pagés, among other personalities, also participated. Mr. Nathanielsz was an honorary guest of Professor Marchal Corrales and Macarena Perán, Professor of Human Anatomy and Embryology, at the University of Jaén, and Propanc’s lead coresearchers.
Left to Right: Professor Marchal Corrales, Dr. Juan Carlos Izpisúa, Professor Macarena Perán & Mr. James Nathanielsz
Dr. Juan Carlos Izpisúa (center), UGR Dignitaries & Mr. James Nathanielsz
For the original article relating to this event, please access the following link:
Juan Carlos Izpisúa provides the UGR with the keys to science against ageing - Canal UGR
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.
More information: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
Investor Contact:
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/efc2b36e-68f2-4988-b67b-58ddcd013f55
https://www.globenewswire.com/NewsRoom/AttachmentNg/60f1b3c0-7f71-48ef-855a-8c4c45f37129